The CD112R/CD112 axis: a breakthrough in cancer immunotherapy

The recent discovery of immune checkpoint inhibitors is a significant milestone in cancer immunotherapy research. However, some patients with primary or adaptive drug resistance might not benefit from the overall therapeutic potential of immunotherapy in oncology. Thus, it is becoming increasingly c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Taofei, Cao, Yuqing, Jin, Tianqiang, Tian, Yu, Dai, Chaoliu, Xu, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431939/
https://www.ncbi.nlm.nih.gov/pubmed/34507594
http://dx.doi.org/10.1186/s13046-021-02053-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431939/
https://www.ncbi.nlm.nih.gov/pubmed/34507594
http://dx.doi.org/10.1186/s13046-021-02053-y

Ejemplares similares